Product Description
For Advanced Malignant Tumors. A kind of tyrosine kinase inhibitor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04128085)
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sino Biopharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20192284 |
CTR20192284 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2023-07-20 |
2025-04-29 |
Primary Completion Date|Start Date|Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|